Agile Therapeutics (AGRX) Provides Regulatory Update and Reiterates Cash Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance
January 10, 2019 4:15 PM ESTDiscussions with FDA on Design of Comparative Wear Study of Twirla® and Xulane® CompletedÂ
Cash Expected to Enable Company to Fund Operations into Second Quarter of 2019
PRINCETON, N.J., Jan. 10, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX), a womens healthcare company, today announced that on January 9, 2019 it received final meeting minutes from its December 11, 2018 meeting with the U.S. Food and Drug Administrations (FDA) Division of Bone, Reproductive, and Urologic Products (DBRUP). The Company met with DBRUP to discuss the design of a comparative... More
